EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 832 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR A Pet Pug Helped Two Sisters Realize They Both Had Breast... October 16, 2020 How to Spend Time with Friends and Family Now that COVID... August 13, 2020 FDA Approves Second CAR T-Cell Therapy for Lymphoma May 22, 2018 Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... May 28, 2025 Load more HOT NEWS FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... Dad Sings “Ave Maria” For His Daughter At Disney World FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative...
